NASDAQ

Viridian Therapeutics, Inc. (VRDN)

439 Thanks from members

Viridian Therapeutics, Inc. (VRDN) is experiencing mixed market sentiment, marked by a recent 22% cut in analyst revenue estimates, intermittent selling pressure, and volatile price action testing key technical support levels.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →